首页> Experimental neurology> Gene therapy device-based delivery of progranulin, prosaposin, and GDNF as a combined precision and neurorestorative therapy in the rat 6-OHDA model of parkinsonism.

Gene therapy device-based delivery of progranulin, prosaposin, and GDNF as a combined precision and neurorestorative therapy in the rat 6-OHDA model of parkinsonism.

导出 LinkOut

翻译打印收藏纠错

第一作者： Chiara,Bertasini

第一单位： Department of Diagnostic and Public Health, Section of Pharmacology, University of Verona, Verona, Italy.

作者： Chiara,Bertasini ^[1] ; Marco,Rossini ^[1] ; Jacopo,Grisotto ^[1] ; Dwaine,Emerich ^[2] ; Matteo,Brunelli ^[3] ; Serena,Pedron ^[3] ; Cristina,Parrado ^[4] ; Lars U,Wahlberg ^[5] ; Johan,Lundkvist ^[6] ; Giovanna,Paolone ^[7]

作者单位： Department of Diagnostic and Public Health, Section of Pharmacology, University of Verona, Verona, Italy. ^[1] Independent Researcher, Glocester, RI, United States. ^[2] Department of Diagnostic and Public Health, Section of Pathology, University of Verona, Verona, Italy. ^[3] AlzeCure Pharma AB, Huddinge, Sweden; Department of NVS, Karolinska Institute, Solna, Sweden. ^[4] Sinfonia Biotherapeutics AB, Huddinge, Sweden; Gloriana Therapeutics Inc, Warren, RI, USA. ^[5] Department of NVS, Karolinska Institute, Solna, Sweden; Sinfonia Biotherapeutics AB, Huddinge, Sweden. ^[6] Department of Diagnostic and Public Health, Section of Pharmacology, University of Verona, Verona, Italy. Electronic address: giovanna.paolone@univr.it. ^[7]

关键词 Cell therapy Glial cell line-derived neurotrophic factor Parkinson's disease Progranulin Prosaposin

DOI 10.1016/j.expneurol.2025.115474

PMID 40992611

发布时间 2025-09-27

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交